Viking Therapeutics (VKTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Naz Rahman from Maxim Group reiterated a Buy rating on the ...

In a report released today, Michael Ulz from Morgan Stanley maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), with a price target of $105.00. Michael Ulz has given his Buy ...

Viking Therapeutics VKTX is set to report third-quarter earnings on Oct. 23, after market close. Since the company lacks a marketed drug in its portfolio, we do not expect it to record revenues ...

While investigating a Stone Age settlement just outside of Varberg, Sweden, archaeologists serendipitously discovered a massive Viking-Age burial ground rife with artifacts. So far, just six percent ...